The estimated Net Worth of David Francis Carroll is at least $8.97 Milhão dollars as of 1 May 2023. Mr. Carroll owns over 63,500 units of IVERIC bio Inc stock worth over $5,272,281 and over the last 8 years he sold ISEE stock worth over $2,262,955. In addition, he makes $1,435,340 as Chief Financial Officer, Senior Vice President, e Treasurer at IVERIC bio Inc.
Sign up
Mr. Carroll ISEE stock SEC Form 4 insiders trading
David has made over 19 trades of the IVERIC bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 63,500 units of ISEE stock worth $178,435 on 1 May 2023.
The largest trade he's ever made was exercising 63,500 units of IVERIC bio Inc stock on 1 May 2023 worth over $178,435. On average, David trades about 14,777 units every 47 days since 2017. As of 1 May 2023 he still owns at least 131,972 units of IVERIC bio Inc stock.
You can see the complete history of Mr. Carroll stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Carroll biography
David Francis Carroll is Chief Financial Officer, Senior Vice President, Treasurer of the Company. Mr. Carroll has served as our senior vice president, chief financial officer and treasurer since April 2017. Mr. Carroll joined us in June 2016 and previously served as senior vice president, finance from June 2016 to April 2017. Prior to joining us, Mr. Carroll served in several senior financial leadership roles at The Medicines Company from May 2008 to June 2016, including vice president, controller from October 2008 to December 2015 and senior vice president, chief accounting officer from January 2016 to June 2016. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Inc., a member of the Roche Group, Novartis AG, and Bristol-Myers Squibb Company. Mr. Carroll is a certified public accountant and received a B.A. in economics from Ursinus College and an M.B.A. from Rutgers University.
What is the salary of David Carroll?
As the Chief Financial Officer, Senior Vice President, e Treasurer of IVERIC bio Inc, the total compensation of David Carroll at IVERIC bio Inc is $1,435,340. There are 3 executives at IVERIC bio Inc getting paid more, with Glenn Sblendorio having the highest compensation of $2,462,150.
How old is David Carroll?
David Carroll is 54, he's been the Chief Financial Officer, Senior Vice President, e Treasurer of IVERIC bio Inc since 2017. There are 9 older and 4 younger executives at IVERIC bio Inc. The oldest executive at IVERIC bio Inc is Calvin Roberts, 67, who is the Independent Director.
What's David Carroll's mailing address?
David's mailing address filed with the SEC is C/O IVERIC BIO, INC., 8 SYLVAN WAY, PARSIPPANY, NJ, 07054.
Insiders trading at IVERIC bio Inc
Over the last 6 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver..., eKeith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.
What does IVERIC bio Inc do?
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).
What does IVERIC bio Inc's logo look like?
Complete history of Mr. Carroll stock trades at IVERIC bio Inc
IVERIC bio Inc executives and stock owners
IVERIC bio Inc executives and other stock owners filed with the SEC include:
-
Glenn Sblendorio,
President, Chief Executive Officer, Director -
David Guyer,
Executive Chairman of the Board -
Anthony S. Gibney,
Exec. VP and Chief Bus. & Strategy Officer -
David Carroll,
Chief Financial Officer, Senior Vice President, Treasurer -
Keith Westby,
Chief Operating Officer, Senior Vice President -
Glenn P. Sblendorio M.B.A.,
CEO & Director -
Dr. Pravin U. Dugel M.D.,
Pres -
David F. Carroll M.B.A.,
Sr. VP, CFO & Treasurer -
Christopher Paul Simms,
Sr. VP & Chief Commercial Officer -
David F. Carroll,
Sr. VP, CFO & Treasurer -
Keith Westby M.B.A.,
Sr. VP & COO -
Calvin Roberts,
Independent Director -
Jane Henderson,
Independent Director -
Adrienne Graves,
Lead Independent Director -
Axel Bolte,
Independent Director -
Kathy Galante,
Vice President, Investor Relations and Corporate Communications -
Mark Blumenkranz,
Director -
Abraham Scaria,
Chief Scientific Officer -
Evelyn Harrison,
Sr. VP & Chief Clinical Operations Officer -
Amy R. Sheehan,
Sr. VP & Chief HR Officer -
Todd D.C. Anderman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Xiao-Ping Dai Ph.D.,
Chief Technical Officer -
Dr. Samir C. Patel,
Co-Founder and Consultant -
Christopher Paul Simms,
SVP, Chief Commercial Officer -
Christine Ann Miller,
Director -
David E Redlick,
Director -
Venture Capital Iv, L.P.Ver...,
-
Anthony S Gibney,
EVP, Chief Business Officer -
Pravin Dugel,
President